XML 51 R42.htm IDEA: XBRL DOCUMENT v3.22.2
REVENUE Disaggregated Revenue Table (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Disaggregation of Revenue [Line Items]          
Accounts Receivable, Allowance for Credit Loss $ 21.3   $ 21.3   $ 21.5
Unbilled Services, Allowance for Credit Loss 11.4   11.4   13.9
Note Receivable, Allowance for Credit Loss 0.7   0.7   0.7
Allowance for Credit Loss 33.4   33.4   36.1
Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings     3.0    
Allowance for Credit Loss, Write Off     (5.7)    
Deferred Revenue, Revenue Recognized     233.6 $ 233.0  
Contract with Customer, Asset, before Allowance for Credit Loss 838.8   838.8   730.8
Revenue, Remaining Performance Obligation, Amount $ 6,132.6 $ 5,616.6 6,132.6 5,616.6  
Long Term Contracts Duration Minimum 1 year        
Long Term Contracts Duration Maximum 8 years        
Contract with Customer, Performance Obligation Satisfied in Previous Period $ 37.4 12.2 69.1 28.7  
Contract with Customer, Liability 544.2   544.2   558.5
Capitalized Contract Cost, Amortization 2.9 3.0 6.0 6.5  
Accrued Sales Commission 40.2   40.2   36.2
Capitalized Contract Cost, Net 15.0   15.0   14.4
Amount of Deferred Costs Related to Long-term Contracts 55.2   55.2   50.6
Amortization of Deferred Sales Commissions 8.7 $ 6.4 15.9 $ 13.3  
Unbilled Contracts Receivable $ 827.4   $ 827.4   716.8
Percent of Revenue Contributed 100.00% 100.00% 100.00% 100.00%  
Revenues $ 3,696.9 $ 3,840.7 $ 7,596.5 $ 8,002.2  
Accounts Receivable, after Allowance for Credit Loss, Current 2,216.4   2,216.4   2,261.5
Allowance for Credit Loss, Receivable, Other, Current (11.4)   (11.4)   (14.0)
Contract with Customer, Asset, after Allowance for Credit Loss, Current $ 827.4   $ 827.4   716.8
Europe [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 13.00% 12.00% 13.00% 11.00%  
North America          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 80.00% 84.00% 80.00% 85.00%  
Other countries [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 7.00% 4.00% 7.00% 4.00%  
UNITED STATES          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 77.30% 80.50% 77.10% 81.70%  
Revenues $ 2,856.9 $ 3,091.3 $ 5,857.5 $ 6,537.4  
Medicare and Medicaid [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 6.00% 6.00% 6.00% 6.00%  
LabCorp Diagnostics [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 61.00% 61.00% 62.00% 63.00%  
Revenues $ 2,255.4 $ 2,365.5 $ 4,709.5 $ 5,123.3  
LabCorp Diagnostics [Member] | Europe [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00%  
LabCorp Diagnostics [Member] | North America          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 61.00% 61.00% 62.00% 63.00%  
LabCorp Diagnostics [Member] | Other countries [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00%  
LabCorp Diagnostics [Member] | Client [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 18.00% 17.00% 17.00% 18.00%  
LabCorp Diagnostics [Member] | Client [Member] | Europe [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00%  
LabCorp Diagnostics [Member] | Client [Member] | North America          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 18.00% 17.00% 17.00% 18.00%  
LabCorp Diagnostics [Member] | Client [Member] | Other countries [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00%  
LabCorp Diagnostics [Member] | Self-Pay [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 7.00% 7.00% 7.00% 6.00%  
LabCorp Diagnostics [Member] | Self-Pay [Member] | Europe [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00%  
LabCorp Diagnostics [Member] | Self-Pay [Member] | North America          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 7.00% 7.00% 7.00% 6.00%  
LabCorp Diagnostics [Member] | Self-Pay [Member] | Other countries [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00%  
LabCorp Diagnostics [Member] | Medicare and Medicaid [Member] | Europe [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00%  
LabCorp Diagnostics [Member] | Medicare and Medicaid [Member] | North America          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 6.00% 6.00% 6.00% 6.00%  
LabCorp Diagnostics [Member] | Medicare and Medicaid [Member] | Other countries [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00%  
LabCorp Diagnostics [Member] | Third party [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 30.00% 31.00% 32.00% 33.00%  
LabCorp Diagnostics [Member] | Third party [Member] | Europe [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00%  
LabCorp Diagnostics [Member] | Third party [Member] | North America          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 30.00% 31.00% 32.00% 33.00%  
LabCorp Diagnostics [Member] | Third party [Member] | Other countries [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00%  
Covance Drug Development [Member]          
Disaggregation of Revenue [Line Items]          
Revenues $ 1,451.9 $ 1,495.2 $ 2,911.2 $ 2,933.4  
Covance Drug Development [Member] | Biopharmaceutical and medical device companies [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed   39.00%   37.00%  
Covance Drug Development [Member] | Biopharmaceutical and medical device companies [Member] | Europe [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed   12.00%   11.00%  
Covance Drug Development [Member] | Biopharmaceutical and medical device companies [Member] | North America          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed   23.00%   22.00%  
Covance Drug Development [Member] | Biopharmaceutical and medical device companies [Member] | Other countries [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed   4.00%   4.00%  
Diagnostics          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 61.00%        
Accounts Receivable, before Allowance for Credit Loss $ 1,066.4   1,066.4   1,193.8
Drug Development          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 39.00%        
Accounts Receivable, before Allowance for Credit Loss $ 1,171.3   $ 1,171.3   $ 1,089.2
Drug Development | Biopharmaceutical and medical device companies [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 39.00%   38.00%    
Drug Development | Biopharmaceutical and medical device companies [Member] | Europe [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 13.00%   13.00%    
Drug Development | Biopharmaceutical and medical device companies [Member] | North America          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 19.00%   18.00%    
Drug Development | Biopharmaceutical and medical device companies [Member] | Other countries [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 7.00%   7.00%    
Notes Receivable [Member]          
Disaggregation of Revenue [Line Items]          
Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings     $ 0.0    
Allowance for Credit Loss, Write Off     0.0    
Unbilled Contracts Receivable [Member]          
Disaggregation of Revenue [Line Items]          
Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings     0.0    
Allowance for Credit Loss, Write Off     (2.5)    
Accounts Receivable [Member]          
Disaggregation of Revenue [Line Items]          
Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings     3.0    
Allowance for Credit Loss, Write Off     $ (3.2)